# US 2023/0054820 A1 · Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054820 A1
- Document ID: US20230054820A1
- Status: Published application
- Kind: A1
- Application number: 17/976,062
- Filed: 2022-10-28
- Published: 2023-02-23
- Earliest claimed: 2004-03-30
- Assignees: Genemedicine Co., Ltd.
- Applicants: Genemedicine Co., Ltd.
- Inventors: Chae-Ok YUN; Joo-Hang KIM
- Web page: https://patentgrep.com/patent/US20230054820A1

## CPC

- C12N 15/86: Viral vectors
- A61K 38/2221: {Relaxins}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2710/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a novel gene delivery system and recombinant adenovirus including the relaxin-encoding sequence to enhance transduction efficiency of transgenes, a pharmaceutical anti-tumor composition including the recombinant adenovirus, a pharmaceutical composition having improved tissue penetration potency and a pharmaceutical composition for treating a disease or disorder associated with accumulation of excess extracellular matrix.

## Claims

### Claim at position 1

1-3. (canceled)

### Claim 4

A gene delivery system comprising a relaxin-encoding nucleotide sequence to enhance a transduction efficiency of the nucleotide sequence of interest into the cell.

### Claim 5 (depends on 4)

The gene delivery system according to claim 4, wherein the cell is a cell in a tissue composed of cells interconnected each other by an extracelluar matrix.

### Claim 6 (depends on 5)

The gene delivery system according to claim 5, wherein the tissue is a tumor tissue.

### Claim 7 (depends on 4)

The gene delivery system according to claim 4, wherein the gene delivery system is a plasmid, a recombinant adenovirus, adeno-associated virus (AAV), retrovirus, lentivirus, herpes simplex virus, vaccinia virus, a liposome or a neosome.

### Claim 8 (depends on 7)

The gene delivery system according to claim 7, wherein the gene delivery system is a recombinant adenovirus.

### Claim 9 (depends on 4)

The gene delivery system according to claim 4, wherein the recombinant adenovirus comprises a deleted E3 region and the relaxin-encoding nucleotide sequence is inserted into the deleted E3 region.

### Claim 10 (depends on 4)

A method for delivering a gene into cells, comprising:
contacting the gene delivery system according to claim 4 to a biosample containing cells.

### Claim 11

A recombinant adenovirus, comprising an adenoviral ITR (inverted terminal repeat) nucleotide sequence and a relaxin-encoding nucleotide sequence, wherein a relaxin protein expressed from the relaxin-encoding nucleotide sequence enhances a penetration potency of the recombinant adenovirus into a tumor tissue and apoptosis of a tumor cell infected with the recombinant adenovirus.

### Claim 12 (depends on 11)

The recombinant adenovirus according to claim 11, wherein the recombinant adenovirus comprises a deleted E3 region and the relaxin-encoding nucleotide sequence is inserted into the deleted E3 region.

### Claim 13 (depends on 11)

The recombinant adenovirus according to claim 11, wherein the recombinant adenovirus comprises an inactivated E1B 19 gene, an inactivated E1B 55 gene or an inactivated E1B 19/E1 B 55 gene.

### Claim 14 (depends on 11)

The recombinant adenovirus according to claim 11, wherein the recombinant adenovirus comprises an active E1A gene.

### Claim 15 (depends on 4)

A method for treating a cancer, comprising:
administering to a subject in need thereof a pharmaceutical anti-tumor composition comprising the gene delivery system of claim 4.
